openPR Logo
Press release

Novel Drug Delivery to be discussed at SMi’s Ophthalmic Drugs Conference and Focus Day 2019

10-22-2019 12:11 PM CET | Associations & Organizations

Press release from: SMI

Ophthalmic Drugs Conference and Focus Day 2019

Ophthalmic Drugs Conference and Focus Day 2019

SMi Reports: Industry leaders confirmed to present on the Focus Day for the upcoming Ophthalmic Drugs conference, in London

With less than 4 weeks until SMi Group’s 3rd annual Ophthalmic Drugs conference taking place on the 18th- 20th November 2019 in London, the event aims to provide great peer-to-peer networking with Global Product Managers, Heads of Drug Development, Senior Directors of Ophthalmology, Heads of Research and Development and many more.

Alongside the conference, a Pre-conference Focus Day will proceed, in which the event theme will be on ‘Novel Drug Delivery though a Complex Barrier’. The focus day will emphasise on alternative delivery approaches to replace intravitreal drug delivery and novel drug development. Also, industry leaders will explore innovations in R&D of novel delivery methods; mechanisms including implants for IOP control; an antagonist prodrug for sustained reduction of intraocular pressure and alternatives to intravitreal delivery.

As there is less than 4 weeks remaining, places are increasingly limited. Interested parties are urged to secure their place at www.ophthalmicdrugs.com/openpr8

Highlights for 2020:

Safety and Efficacy of a Novel Intracapsular Drug Delivery Platform

- iVeena has developed an intracapsular drug delivery platform that enables bi-directional drug delivery to anterior and posterior eye segments
- The initial platform technology application is IVMED-20, a bioerodible dexamethasone delivery implant placed during cataract surgery to prophylax cystoid macular edema, as well as, control inflammation and pain from the procedure
Michael Burr, Vice President of Product Development, iVeena

This year’s Focus Day Chairman will be MHRA’s Medical Assessor, Peter Morgan-Warren, on ‘Regulatory perspectives on novel ocular drug delivery’ covering:

- Novel ocular drug delivery and the regulatory framework – clinical considerations
- Combination products, devices and borderline products

For the full speaker line-up, as well as the latest event details, the brochure is available at www.ophthalmicdrugs.com/openpr8

Ophthalmic Drugs Conference
18th – 20th November 2019
Copthorne Tara Hotel, London, UK

Proudly sponsored by:
EXPERIMENTICA | ProMed Pharma

Contacts:
Sponsorship, exhibition and branding packages: Alia Malick +44 (0)20 7827 6168 / amalick@smi-online.co.uk

Media enquiries contact Neill Howard +44 (0) 207 827 6164 / nhoward@smi-online.co.uk

--END—

45 Curlew Street

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Novel Drug Delivery to be discussed at SMi’s Ophthalmic Drugs Conference and Focus Day 2019 here

News-ID: 1854397 • Views: 116

More Releases from SMI

11-08-2019 | Health & Medicine
SMI
RNA Therapeutics 2020 to Highlight Downregulating Therapeutic Technologies
SMi Reports: The morning session on day two of SMi’s RNA Therapeutics conference will pay a particular focus to “Downregulating Therapeutic Technologies”. SMi are proud to host the 11th annual RNA Therapeutics conference on February 19th – 20th 2020 in London. This year’s event will maintain a focus on the latest research and developments on delivery system technologies aimed at tackling difficult targets within the human body. An early
Registration closing soon for SMi’s Social Media in the Defence and Military S …
SMi reports: Two weeks left to secure your place at the upcoming 9th annual Social Media in the Defence Sector conference, taking place in London Taking place on 20th and 21st November, the 9th annual Social Media in the Defence Sector conference, taking place in London, will feature the biggest speaker line-up to date, with leading militaries at the cutting edge of social media innovation from the UK, USA, Canada, Italy,
11-01-2019 | Health & Medicine
SMI
Exclusive interview from conference speaker John Lisman released ahead of Parall …
SMi has released an exclusive interview with industry expert John Lisman, Attorney, Consultant and Trainer of Lisman Legal Life sciences B.V., ahead of the upcoming Parallel Trade conference this February. SMi’s Parallel Trade conference, taking place on 4th-5th February 2020 in London, will explore shortages of medicines, current and ongoing challenges posed by Parallel Trading, potential implications of Brexit and IP exhaustion rights. As the only B2B parallel trade conference in
11-01-2019 | Health & Medicine
SMI
Exclusive interview from conference speaker Torsten Kneuss released ahead of SMi …
SMi has released an exclusive interview with industry expert Torsten Kneuss, Quality Assurance Manager Combination Products of Bayer, ahead of the upcoming Pre-Filled Syringes and Injectable Drug Devices conference this January. SMi’s Pre-Filled Syringes and Injectable Drug Devices conference, taking place on 15th-16th January 2020 in London, will bring together pharmaceutical experts, clinical researchers and manufacturers in the pre-filled syringes industry to examine innovations in device engineering and components, enhancement of

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning